-
TransCode Therapeutics and Quantum Leap Advance TTX-MC138 Development with IND Amendment Submission for Phase 2a Trial
NASDAQ: $RNAZ A Significant Step Forward in Oncology Treatment TransCode Therapeutics, Inc. and Quantum Leap Healthcare Collaborative (QLHC) have jointly announced a noteworthy progression in their ongoing research and development efforts. The companies have officially submitted an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA). This submission pertains to the…
-
Hoth Therapeutics Reports Significant Initial Results in Novel Cancer Therapy Trial
NASDAQ: $HOTH A recent press release from PR Newswire highlights exciting early data from Hoth Therapeutics regarding their ongoing clinical study involving a novel treatment approach for cancer patients whose tumors express the Epidermal Growth Factor Receptor (EGFR). The announcement, specifically concerning the open-label pharmacokinetic (PK) cohort of the study, signals a promising step forward…
-
PDS Biotech Secures New U.S. Patent for Core Technology
NASDAQ: $PDSB Pharmaceutical development is a meticulous and often lengthy process, where intellectual property protection is paramount to innovation. In a significant move for the sector, PDS Biotech recently announced the issuance of a new U.S. Patent. This patent specifically covers the fundamental technology platform that underpins one of the company’s key investigational products, PDS0.…
-
Lexicon Pharmaceuticals Advances Pilavapadin Towards Late-Stage Trials for Diabetic Neuropathic Pain
NASDAQ: $LXRX Lexicon Pharmaceuticals recently shared significant news regarding its investigational drug, pilavapadin, marking a crucial step forward in the potential treatment landscape for diabetic peripheral neuropathic pain (DPNP). The company announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). Understanding the Significance of the FDA Meeting…
-
Abpro’s ABP-102 Takes Center Stage at J.P. Morgan Healthcare Conference via Celltrion Presentation
NASDAQ: $ABP The recent announcement surrounding Abpro Therapeutics’ lead product candidate, ABP-102, has generated considerable excitement within the biotechnology sector. According to a press release published on GlobeNewswire, details regarding this promising program were prominently featured during a presentation by Celltrion Healthcare Co., Ltd. at the prestigious 44th Annual J.P. Morgan Healthcare Conference. For those…